Next Generation Nasal Spray Against Influenza
Avir Green Hills Biotechnology (GHB, Vienna, Austria, www.greenhillsbiotech.com) has started the first clinical Phase 1 study for its novel influenza vaccine FLUVACC. FLUVACC is based on the deletion of the NS1 gene.
Avir Green Hills Biotechnology (GHB, Vienna, Austria, www.greenhillsbiotech.com) has started the first clinical Phase 1 study for its novel influenza vaccine FLUVACC. FLUVACC is based on the deletion of the NS1 gene. The first eight volunteers were vaccinated in collaboration with the Medical University Vienna at the General Hospital. The protection rate is expected to surpass the rate achieved with currently available vaccines. FLUVACC is administered as an intranasal spray and differs in its method of production from the currently available flu vaccines. In contrast to conventional influenza vaccines, which are manufactured in chicken eggs, FLUVACC is produced in cultured cells (vero cells). The use of reverse genetics allows quick and efficient fine-tuning to circulating virus strains.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
